Status:
COMPLETED
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
Lead Sponsor:
Eli Lilly and Company
Conditions:
Osteoporosis
Eligibility:
FEMALE
50-85 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effects of teriparatide on skeleton images in postmenopausal women with osteoporosis. Teriparatide is a bone formation agent that stimulates the production...
Eligibility Criteria
Inclusion
- Ambulatory with osteoporosis
- Hip or spine bone mineral density (BMD) measurement more than 2.5 standard deviations below the average bone mass of young healthy women or more than 2.0 standard deviations in women who have a history of a vertebral or nonvertebral fragility fracture.
Exclusion
- Diseases of bone other than osteoporosis
- Treatment with estrogens in the 3 months prior to enrollment or for more than 2 months in the past year
- Treatment with oral bisphosphonates in the 3 months prior to enrollment or for more than 2 months in the past year; treatment with intravenous bisphosphonates in the 12 months prior to enrollment
- Increased risk for the development of osteosarcoma
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00259298
Start Date
November 1 2005
End Date
July 1 2009
Last Update
August 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
London, United Kingdom, SE1 9RT